Method of treatment of egfr inhibitor toxicity

Details Method of treatment of egfr inhibitor toxicity Method of treatment of egfr inhibitor toxicity

A - Human Necessities

61

K

A61K 31/37 (2006.01) A61P 39/00 (2006.01)

Patent

CA 2719442

The invention provides a method of treating and/or preventing a toxicity associated with epidermal growth factor receptor (EGFR) inhibitor therapy in a subject, the method comprising administering to the subject an effective amount of a steroid sulfatase (STS) inhibitor. The toxicity may be ocular toxicity; or dermatologic toxicity, such as papulopustular rash. The EGFR inhibitor may be selected from the group consisting of: a small molecule; an antibody or derivative or fragment thereof; another agent that targets the extracellular or intracellular domain of the EGFR, such as a tyrosine kinase inhibitor selected from the group consisting of: erlotinib; gefitinib; lapatinib; and any combination thereof. The EGFR inhibitor may also be antibody selected from the group consisting of: cetuximab; panitumumab; and any combination thereof. Preferably the STS inhibitor is selected from the group consisting of. alternative STS substrates; reversible STS inhibitors; and irreversible STS inhibitors; and any combination thereof. A preferred STS inhibitor is the irreversible nonsteroidal STS inhibitor STX64. In some embodiments, the subject receiving EGFRI therapy has a cancer comprising cells that express wildtype k-ras and/or wildtype b-raf. In other embodiments, the cancer may be hormone-dependent. Cancers that may be treated with EGFRI therapy include colorectal cancer and non-small cell lung cancer.

Affiliated with

Also associated with

Rating

Method of treatment of egfr inhibitor toxicity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of treatment of egfr inhibitor toxicity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment of egfr inhibitor toxicity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2088844